News and Announcements
Antisense Therapeutics ATL1102 for MS Phase IIB IND Submitted to FDA for Approval
- Published June 26, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Antisense Therapeutics (ANP) has advised that the ATL1102 for Multiple Sclerosis (MS) Phase IIb IND application has been submitted to the US Food and Drug Administration (FDA) for its review.
KEY TAKEAWAYS:
- The Company’s IND application is for a Phase IIb trial in 195 R-MS patients.
- ANP is seeking to secure non-dilutive funding for the conduct of the Phase IIb trial from a US Federal Agency. IND clearance is required for receipt of such grant funding.
The ATL1102 Phase IIb IND application was composed of over 24,000 pages of ATL1102 information and data that required specific formatting and critical review by the Company’s US Regulatory Agents to ensure compliance with the FDA requirements for electronic IND submission.
Mark Diamond, CEO of Antisense Therapeutics said; “We are pleased to have reached this significant milestone in the development of ATL1102 for MS and look forward to the prospect of positive outcomes following the FDA’s review”.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
